IL143528A0 - Therapeutic agents containing botulinum toxin for the suppression of snoring noises - Google Patents

Therapeutic agents containing botulinum toxin for the suppression of snoring noises

Info

Publication number
IL143528A0
IL143528A0 IL14352899A IL14352899A IL143528A0 IL 143528 A0 IL143528 A0 IL 143528A0 IL 14352899 A IL14352899 A IL 14352899A IL 14352899 A IL14352899 A IL 14352899A IL 143528 A0 IL143528 A0 IL 143528A0
Authority
IL
Israel
Prior art keywords
bont
clostridium toxin
carrier
added
suppression
Prior art date
Application number
IL14352899A
Other languages
English (en)
Original Assignee
Biotecon Ges Fur Biotechnologi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotecon Ges Fur Biotechnologi filed Critical Biotecon Ges Fur Biotechnologi
Publication of IL143528A0 publication Critical patent/IL143528A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • Y10S530/825Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14352899A 1998-12-10 1999-12-10 Therapeutic agents containing botulinum toxin for the suppression of snoring noises IL143528A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19856897A DE19856897A1 (de) 1998-12-10 1998-12-10 Therapeutikum zur Unterdrückung von Schnarchgeräuschen
PCT/EP1999/009791 WO2000033863A2 (de) 1998-12-10 1999-12-10 Therapeutikum zur unterdrückung von schnarchgeräuschen

Publications (1)

Publication Number Publication Date
IL143528A0 true IL143528A0 (en) 2002-04-21

Family

ID=7890562

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14352899A IL143528A0 (en) 1998-12-10 1999-12-10 Therapeutic agents containing botulinum toxin for the suppression of snoring noises
IL143528A IL143528A (en) 1998-12-10 2001-06-03 Drugs that contain botulinum toxin to reduce snoring noise

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL143528A IL143528A (en) 1998-12-10 2001-06-03 Drugs that contain botulinum toxin to reduce snoring noise

Country Status (21)

Country Link
US (1) US6573241B1 (pt)
EP (1) EP1137430B1 (pt)
JP (1) JP4700811B2 (pt)
KR (1) KR100859556B1 (pt)
CN (1) CN1186095C (pt)
AT (1) ATE234108T1 (pt)
AU (1) AU764744B2 (pt)
BR (1) BR9915800A (pt)
CA (1) CA2353469A1 (pt)
CZ (1) CZ295769B6 (pt)
DE (2) DE19856897A1 (pt)
DK (1) DK1137430T3 (pt)
ES (1) ES2192880T3 (pt)
HK (1) HK1040636B (pt)
HU (1) HUP0104702A3 (pt)
IL (2) IL143528A0 (pt)
NO (1) NO328762B1 (pt)
PL (1) PL202908B1 (pt)
PT (1) PT1137430E (pt)
RU (1) RU2243783C2 (pt)
WO (1) WO2000033863A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US20100104631A1 (en) * 2001-08-13 2010-04-29 Lipella Pharmaceuticals Inc. Method of treatment for bladder dysfunction
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US7183066B2 (en) * 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US20150258183A1 (en) 2006-06-07 2015-09-17 Botulinum Toxin Research Associates, Inc. Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
EP1898947A2 (en) * 2005-06-14 2008-03-19 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US8926991B2 (en) 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
JP5368793B2 (ja) 2005-07-18 2013-12-18 ユニバーシティ オブ マサチューセッツ ロウエル ナノエマルジョンを製造および使用するための組成物および方法
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
TR201901443T4 (tr) 2005-12-01 2019-02-21 Univ Massachusetts Lowell Botulinum nanoemülsiyonları.
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
BRPI0719732A2 (pt) 2006-12-01 2017-05-16 Anterios Inc nanopartículas de peptídeo e usos para as mesmas
EP2494958A1 (en) * 2006-12-01 2012-09-05 Anterios, Inc. Amphiphilic Entity Nanoparticles
ES2660906T3 (es) 2007-05-31 2018-03-26 Anterios, Inc. Nanopartículas de ácido nucleico y usos de las mismas
WO2009158687A1 (en) * 2008-06-26 2009-12-30 Anterios, Inc. Dermal delivery
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US20100166739A1 (en) * 2008-12-30 2010-07-01 Lipella Paharmaceuticals Inc. Methods and Compositions for Diagnosing Urological Disorders
JP2013510193A (ja) * 2009-11-09 2013-03-21 サンダース,イラ 神経毒を用いる睡眠呼吸障害の処置
PL2677029T3 (pl) 2011-05-19 2017-10-31 Ipsen Bioinnovation Ltd Sposoby wytwarzania poddanych obróbce proteolitycznej polipeptydów
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
JP6156954B2 (ja) 2012-11-21 2017-07-05 イプセン バイオイノベーション リミテッド タンパク分解性にプロセシングされたポリペプチドの製造方法
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
KR102487144B1 (ko) 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 큰 물질의 경피 전달

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551473A (en) 1984-04-26 1985-11-05 Schossow George W Method of inhibiting snoring and obstructive sleep apnea
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
AU683275B2 (en) * 1993-06-10 1997-11-06 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
AU688452B2 (en) * 1993-12-28 1998-03-12 Allergan, Inc. Botulinum toxins for treating various disorders and associated pain
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US9310728B2 (en) 2013-06-13 2016-04-12 Lexmark International, Inc. Latch mechanism for a fuser assembly having a heat transfer roll

Also Published As

Publication number Publication date
PL349334A1 (en) 2002-07-15
US6573241B1 (en) 2003-06-03
CN1329501A (zh) 2002-01-02
CN1186095C (zh) 2005-01-26
HK1040636A1 (en) 2002-06-21
DE59904569D1 (de) 2003-04-17
CZ20012058A3 (cs) 2001-09-12
KR20010089527A (ko) 2001-10-06
JP2002531516A (ja) 2002-09-24
NO328762B1 (no) 2010-05-10
ES2192880T3 (es) 2003-10-16
CZ295769B6 (cs) 2005-11-16
NO20012716D0 (no) 2001-06-01
HUP0104702A3 (en) 2003-09-29
EP1137430A2 (de) 2001-10-04
JP4700811B2 (ja) 2011-06-15
BR9915800A (pt) 2001-09-25
DE19856897A1 (de) 2000-06-15
EP1137430B1 (de) 2003-03-12
PT1137430E (pt) 2003-07-31
WO2000033863A2 (de) 2000-06-15
AU764744B2 (en) 2003-08-28
HUP0104702A2 (hu) 2002-04-29
IL143528A (en) 2008-04-13
PL202908B1 (pl) 2009-08-31
RU2243783C2 (ru) 2005-01-10
KR100859556B1 (ko) 2008-09-22
HK1040636B (zh) 2003-05-30
NO20012716L (no) 2001-06-01
ATE234108T1 (de) 2003-03-15
CA2353469A1 (en) 2000-06-15
AU3037400A (en) 2000-06-26
WO2000033863A3 (de) 2000-11-02
DK1137430T3 (da) 2003-06-16

Similar Documents

Publication Publication Date Title
IL143528A0 (en) Therapeutic agents containing botulinum toxin for the suppression of snoring noises
MXPA02002895A (es) Tratamiento topico de infecciones por estreptococcus.
MX9706095A (es) Enzima multifuncional.
PL319833A1 (en) Compounds and composition for carrying active media
BG100974A (en) Vaccines against papillomavirus
EP1820862A3 (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
ATE552891T1 (de) Kombination von sauren-proteaseenzymen und sauren pufferlösungen sowie deren verwendung
AU9125798A (en) Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
CA2191754A1 (en) Modification of Clostridial Toxins for Use as Transport Proteins
AU1916995A (en) 4-amino derivatives of mycophenolic acid with immunosuppressant activity
RU2001116080A (ru) Терапевтический агент для подавления шумов храпа
WO1998001158A3 (de) Hämoglobin-hydroxyethylstärke-konjugate als sauerstoff-transport-mittel
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
AU1436699A (en) The use of polyols in combating yeast infection and polyol preparations for saiduse
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
AU5956398A (en) Remedies for lymphocytic tumors
CA2253287A1 (en) A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium
WO2002026245A3 (en) Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
WO1996030042A3 (en) Methods of treating inflammation and compositions therefor
AU1041397A (en) Antigenic protein originating in malassezia
US5798392C1 (en) Sulfonyl fluorides for the treatment of alzheimer's disease
MXPA05003616A (es) Composiciones que comprenden anfotericina b altamente purificada.
GB2306885B (en) Supersaturated Pharmaceutical Compositions
WO2000042987A3 (en) Targeted vesicular constructs for cytoprotection and treatment of h. pylori infections
IE840977L (en) Pharmaceutical preparations

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed